Morgan Stanley
-
-
-
-
-
-
-
Morgan Stanley on Vertex (VRTX): 'Exa-cel filing timeline better than feared'
-
-
-
-
-
-
-
Morgan Stanley Downgrades bluebird bio (BLUE) to Underweight, 'commercialization will remain challenging'
-
-
-
-
-
-
-
Morgan Stanley Reiterates Equalweight Rating on bluebird bio (BLUE) While Discussing Timing and Impact of Clinical Hold
-
-
-
-
-
-
-
bluebird bio (BLUE) PT Lowered to $185 at Morgan Stanley
-
-
-
-
-
-
-
Pre-Open Movers 10/02: (RIGL) (SNCR) (TRN) Higher; (JWN) (GNW) (ROKU) Lower (more...)
-
-
-
-
-
-
-
bluebird bio (BLUE) PT Raised to $87 at Morgan Stanley
-
-
-
-
-
-
-
Market Wrap: China Data Stunts Markets; Weight Watchers Inks Major Deal; Western Digital/SanDisk Deal Nears
-
211,042 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

